Health Care · Report · File No. 261118-825
FDA nominee Overton's confirmation in doubt as Senate vote nears; no pullout confirmed
Heidi Overton, Trump's pick to lead the FDA, was short of Republican votes on the Senate health committee, and the White House had begun looking for a replacement. Our fact desk could not confirm a report that her nomination was dropped.
Every quote in this story (2) was matched word for word against its source. How we work

The White House was reported on Nov. 17 to be dropping Heidi Overton's nomination to lead the Food and Drug Administration (FDA). The Axios report behind that claim could not be loaded by our fact desk. The two outlets we could read did not report a formal withdrawal, so we are not treating one as confirmed.
What those reports do show is a nomination in serious trouble. CBS News reported on Nov. 17 that Overton was struggling to find enough Republican votes on the Senate Health, Education, Labor and Pensions (HELP) Committee. The committee's vote was scheduled for Wednesday morning, and the nomination could be pulled if she lacked support 1.
The vote count
NBC News reported that Overton needs 11 of the committee's 21 votes. If every Democrat opposes her, she cannot lose a single Republican 2. CBS reported that no Democrats on the panel are expected to back her 1.
Sen. Bill Cassidy, a Louisiana Republican and the committee chairman, has not said how he will vote. On "Face the Nation" on Sunday he said he was unsure whether the committee would advance her 1. Sens. Susan Collins of Maine and Lisa Murkowski of Alaska had not said how they would vote 12.
Do we want a series of short-term administrators who probably will have more influence from the secretary.
The abortion pill question
Mifepristone, a pill used in more than half of U.S. abortions, is central to the fight 1. The FDA is set to finish a safety review of the drug in March, and Overton would oversee it if confirmed 2.
At her September hearing, Overton sidestepped questions on the drug. She said only that it met FDA standards and that she did not want to prejudge the review 2. While at the American First Policy Institute, a conservative group, she called the FDA's decision to allow mail delivery of mifepristone "dangerous to women" 2.
Opposition comes from both sides. Susan B. Anthony Pro-Life America urged the Senate to delay confirmation and wants the FDA to commit to banning mail-order mifepristone. Sen. Josh Hawley, a Missouri Republican, is also among the skeptics 1. Democrats have focused on her abortion record 2.
I have not taken a position
What happens next
CBS reported that a source said the White House knows it has a problem and has begun looking for a new candidate. The administration has also talked with people who could serve as acting commissioner and avoid Senate confirmation. Sources said Sen. Roger Marshall, a Kansas Republican who lost his reelection bid this month, is seeking the job 1.
Time is short. Democrats take control of the Senate on Jan. 3. A former congressional aide told NBC that if Overton is not confirmed by then, her nomination would likely be returned to the White House. Trump would have to renominate her before a Democratic-controlled Senate, where her chances would be slim 2.
The FDA has had no Senate-confirmed commissioner since Dr. Marty Makary left in the spring. Kyle Diamantas has been acting commissioner since then 12.
That matters because the agency approves drugs and sets the rules for medicines that older Americans rely on. Whoever leads it will also oversee the abortion pill review. This story will be updated when the White House or the committee confirms what happens.
The Record
Republish this story on your site or in your newsletter
Any site, blog or newsletter may run this story free of charge. Keep the credit line and its link to the original, do not sell it, and edit only for length or house style (the full terms). Photos carry their own licenses, noted under each photo on this page, so use the text alone unless a credit says otherwise.
Paste it into your editor's HTML view. The one-pixel image at the end tells our newsroom the story ran; it stores no reader data.
Sources
- CBS News, “Trump FDA nominee Heidi Overton struggling to win enough GOP support to be confirmed” (2026-11-17). cbsnews.com/news/trump-fda-nominee-heidi-overton-confirmatio
- NBC News, “Trump's FDA pick Dr. Heidi Overton faces Republican doubts as confirmation nears” (2026-11-12). nbcnews.com/health/health-news/trump-fda-overton-confirmatio
Found an error? Tell the newsroom. Corrections are noted at the top of the story.
More from the files
White House pulls FDA nominee Heidi Overton; Cassidy says a viable path was abandoned
The White House withdrew Dr. Heidi Overton's nomination to lead the Food and Drug Administration the night before a Senate committee vote. Sen. Bill Cassidy says she had the votes, so the FDA stays under an acting chief.
Senate health panel sets Nov. 18 vote on Trump's FDA nominee Heidi Overton
The committee will vote on Dr. Heidi Overton a week from today, and its chairman, Sen. Bill Cassidy, says he is undecided. The Food and Drug Administration (FDA) has had no confirmed leader since its last commissioner resigned in May.
Abortion pill access hangs over Senate panel's Wednesday vote on Trump's FDA pick
A Senate committee votes Nov. 18 on Dr. Heidi Overton, Trump's pick to lead the Food and Drug Administration. The country's best-known anti-abortion group wants senators to hold her up until the administration ends mail-order access to the abortion pill mifepristone. Republicans can lose only one vote.
Delivered free to your door*
The Morning Edition
One short email at 7 a.m. Eastern: the day's top files, one clip worth your time, and the race to watch. Plain English, large type, no clutter.
*Your inbox. Free. Unsubscribe with one click, any time.


